CBSC (Cardiac Biotech Solutions) EBIT: $-0.44 Mil (TTM As of Jun. 2025)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

What is Cardiac Biotech Solutions EBIT?

Cardiac Biotech Solutions CBSC EBIT is $-0.44 Mil as of Jun. 2025.

Cardiac Biotech Solutions's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2025 was $-0.11 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2025 was $-0.44 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cardiac Biotech Solutions's annualized ROC % for the quarter that ended in Jun. 2025 was -83.92%. Cardiac Biotech Solutions's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cardiac Biotech Solutions's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -8.21%.

Cardiac Biotech Solutions (OTCPK:CBSC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cardiac Biotech Solutions's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

	ROC % (Q: Jun. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2025 )	+	Invested Capital (Q: Jun. 2025 ))	/ count )
=	-0.804 * ( 1 - 0% )	/	( (0.94	+	0.976)	/ 2 )
=	-0.804	/	0.958
=	-83.92 %

where

	Invested Capital		(Q: Mar. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.167	-	1.152	-	( 0.05	-	max(0, 2.017	-	0.092	+	0.05	))
=	0.94

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.173	-	1.271	-	( 0.022	-	max(0, 2.172	-	0.098	+	0.022	))
=	0.976

Note: The Operating Income data used here is four times the quarterly (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Cardiac Biotech Solutions's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2025		Q: Jun. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.42	/	( ( (0 + max(-1.712, 0))	+	(0 + max(-1.738, 0)) )	/	2 )
=	-0.42	/	( ( 0	+	0 )	/	2 )
=	-0.42	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Mar. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.007	+	0.028	+	0.007)	-	(1.152	+	0.135	+	0.467)
=	-1.712

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.042	+	0.028	+	0.006)	-	(1.271	+	0.125	+	0.418)
=	-1.738

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cardiac Biotech Solutions's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2025 )
	=	-0.435	/	5.299
	=	-8.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiac Biotech Solutions EBIT Related Terms

Cardiac Biotech Solutions EBIT Historical Data

* Premium members only.

The historical data trend for Cardiac Biotech Solutions's EBIT can be seen below:

Cardiac Biotech Solutions EBIT Chart

Cardiac Biotech Solutions Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Mar25

EBIT

-3.98

-4.80

-2.10

-1.65

-1.69

Cardiac Biotech Solutions Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Mar25	Jun25
EBIT	Get a 7-Day Free Trial												-0.36	-0.26	-0.33	0.00	-0.11

CBSC vs LUCY, NXGL, MHUAF: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Cardiac Biotech Solutions's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiac Biotech Solutions EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cardiac Biotech Solutions's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cardiac Biotech Solutions's EV-to-EBIT falls into.

Save Embed

Cardiac Biotech Solutions EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-0.44 Mil mean?

Cardiac Biotech Solutions (CBSC) has a EBIT of $-0.44 Mil as of Jun. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cardiac Biotech Solutions.

Is Cardiac Biotech Solutions' EBIT too high?

Cardiac Biotech Solutions' current EBIT is $-0.44 Mil.

How does Cardiac Biotech Solutions' EBIT compare to LUCY and NXGL?

Cardiac Biotech Solutions' EBIT of $-0.44 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Devices & Instruments company?

A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Cardiac Biotech Solutions. Cardiac Biotech Solutions's current EBIT is $-0.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cardiac Biotech Solutions stock overvalued right now?

Cardiac Biotech Solutions (CBSC) has a current EBIT of $-0.44 Mil. The current EBIT is $-0.44 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current EBIT is $-0.44 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiac Biotech Solutions Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies LUCY NXGL MHUAF RSCF GCTK YBGJ FEMY ECIA UEEC BNGO ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST XSWX:STMN TSE:4543

Address 10845 Griffith Peak Drive, Suite 200, Las Vegas, NV, USA, 89135

Website https://www.cbscientificinc.com

Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.